Bioethics, Ltd. (BOTH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBioethics, Ltd. (BOTH) trades at $0.0051. Bioethics, Ltd. is a shell company based in Ogden, Utah, with no significant operations. The company intends to identify and potentially acquire a business opportunity. Sector: Financials.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for BOTH: BOTH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Bioethics, Ltd. (BOTH) Financial Services Profile
Bioethics, Ltd., incorporated in 1990 and based in Ogden, Utah, operates as a shell company within the financial services sector. Currently without significant operations, the company's core strategy involves seeking and potentially acquiring an interest in a viable business opportunity, reflecting its speculative nature.
What Is the Investment Thesis for BOTH?
Investing in Bioethics, Ltd. is highly speculative due to its nature as a shell company with no current operations. The potential upside relies entirely on the company's ability to identify and acquire a promising business. Currently, the company's market capitalization is $0.00B, and it has a negative P/E ratio of -0.17. The absence of a dividend yield further underscores the speculative nature. The primary value driver is the potential for a successful acquisition that transforms the company's operational profile. Key risks include the failure to find a suitable target, dilution of shareholder value through future equity offerings, and the inherent uncertainty associated with shell company investments. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
BOTH Key Highlights
Market capitalization of $0.00B reflects the company's lack of current operations.
- Negative P/E ratio of -0.17 indicates the company is not currently profitable.
- Beta of -6.41 suggests a high degree of volatility and inverse correlation with the market.
- Absence of dividend yield indicates no current return of capital to shareholders.
- The company's sole activity is seeking a business opportunity for potential acquisition.
Who Are BOTH's Competitors?
BOTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| COLA Columbus Acquisition Corp | $2.86 | -60.82% | $12.9M | — |
| ASPC A SPAC III Acquisition Corp. | $10.83 | -0.58% | $25.3M | — |
| RIBB Ribbon Acquisition Corp | $7.96 | -5.24% | $39.9M | — |
| BKHA Black Hawk Acquisition Corporation | $12.38 | +0.24% | $51.4M | — |
| IBAC IB Acquisition Corp. | $10.90 | -0.09% | $54.6M | — |
| FVN Future Vision II Acquisition Corp. | $8.01 | -16.61% | $60.4M | — |
| APAC StoneBridge Acquisition Corporation | $10.27 | 0.00% | $63.0M | — |
| BSAA BEST SPAC I Acquisition Corp. | $11.18 | -1.11% | $67.3M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BOTH's Key Strengths?
Existing corporate structure for acquisitions.
- Potential for rapid growth through acquisition.
- Flexibility to pursue various business opportunities.
- Publicly listed status provides access to capital markets.
What Are BOTH's Weaknesses?
Lack of current operations and revenue.
- Dependence on identifying and acquiring a suitable target.
- High degree of uncertainty and speculative nature.
- Potential for dilution of shareholder value.
What Are the Key Risks for BOTH?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to identify a suitable acquisition target.
- Dilution of shareholder value through future equity offerings.
- High degree of uncertainty and speculative nature of the investment.
- Limited liquidity and trading volume on the OTC market.
- Risk of delisting and loss of investment.
What Threats Does BOTH Face?
- Failure to identify a suitable acquisition target.
- Competition from other shell companies and SPACs.
- Changes in regulatory environment.
- Economic downturn impacting acquisition opportunities.
What Are BOTH's Competitive Advantages?
- First-mover advantage in identifying a specific acquisition target (if applicable).
- Established corporate structure for facilitating acquisitions.
- Access to capital for funding acquisitions (if applicable).
- Network of advisors and industry contacts for deal sourcing.
What Does BOTH Do?
Bioethics, Ltd., established in 1990, functions as a shell company, indicating that it lacks substantial ongoing business operations. Headquartered in Ogden, Utah, the company's primary objective is to identify, investigate, and potentially acquire an interest in an existing business. This model is characterized by a period of inactivity while the company searches for a suitable acquisition target. Bioethics, Ltd. does not currently offer specific products or services, as its activities are centered on the pursuit of a business opportunity that aligns with its strategic objectives. The company's future direction is contingent upon the successful identification and acquisition of a target business, which would then define its operational focus and market presence. Given its status, Bioethics, Ltd. does not have a defined geographic reach or competitive positioning until it completes an acquisition.
What Products and Services Does BOTH Offer?
- Operate as a shell company with no significant business operations.
- Seek and investigate potential business opportunities.
- Intend to acquire an interest in a business if warranted.
- Maintain a corporate structure to facilitate future acquisitions.
- Explore various strategic alternatives to enhance shareholder value.
- Comply with regulatory requirements for shell companies.
How Does BOTH Make Money?
- Identify and evaluate potential acquisition targets.
- Raise capital through equity or debt financing.
- Acquire an interest in a target business.
- Potentially execute a reverse merger with a private company.
What Industry Does BOTH Operate In?
Bioethics, Ltd. operates within the shell company segment of the financial services industry. Shell companies are often used as vehicles for mergers, acquisitions, or reverse takeovers, providing a faster and potentially less regulated path to public listing for private companies. The industry is characterized by high risk and speculative investments, as the success of these companies depends entirely on their ability to identify and acquire viable businesses. The competitive landscape includes other shell companies and special purpose acquisition companies (SPACs), all vying for attractive acquisition targets.
Who Are BOTH's Key Customers?
- Currently, Bioethics, Ltd. does not have customers due to its status as a shell company.
- Future customers will depend on the business acquired.
- Potential investors seeking exposure to a specific industry through acquisition.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Bioethics, Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Bioethics, Ltd. stands at 20.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Bioethics, Ltd. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Ogden, US. The company is led by CEO Mark A. Scharmann. BOTH has traded publicly since 2002.
BOTH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
BOTH Latest News
-
Amazon's 2-tier end table with 5,000+ perfect ratings is on sale for just $14
TheStreet · Sep 6, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 17, 2019
-
Stocks That Managed to Breach 52-Week Lows Friday
· Jul 26, 2019
BOTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BOTH.
Price Targets
Wall Street price target analysis for BOTH.
BOTH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BOTH; grades run from A+ (80-100) to F (below 30).
Leadership: Mark A. Scharmann
CEO
Mark A. Scharmann serves as the CEO of Bioethics, Ltd. His professional background includes experience in corporate management and strategic planning. While specific details regarding his prior roles and educational qualifications are not available, he brings a focus on identifying and evaluating potential business opportunities for the company. His leadership is centered on guiding Bioethics, Ltd. through its strategic objectives and ensuring compliance with regulatory requirements.
Track Record: As CEO of Bioethics, Ltd., Mark A. Scharmann's primary responsibility is to identify and pursue a viable business opportunity for the company. Given the company's current status as a shell corporation, his track record is closely tied to the progress in finding and securing a suitable acquisition target. The success of his tenure will be determined by the company's ability to complete a successful acquisition and generate value for shareholders.
BOTH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bioethics, Ltd. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and increased volatility. This tier is often populated by shell companies, defunct businesses, or companies with regulatory issues.
- OTC Tier: OTC Other
- Limited information and disclosure due to OTC Other listing.
- Low trading volume and illiquidity.
- Potential for price manipulation and fraud.
- Uncertainty regarding the company's future prospects.
- Risk of delisting and loss of investment.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's business plan and prospects.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Established corporate structure (incorporated in 1990).
- Publicly listed status provides some level of regulatory oversight.
- Engagement of a CEO (Mark A. Scharmann).
- Intention to acquire a business opportunity.
- Compliance with OTC market regulations (to the extent known).
Bioethics, Ltd. Financials Stock: Key Questions Answered
What does Bioethics, Ltd. do?
Bioethics, Ltd. operates as a shell company, meaning it currently has no active business operations. Its primary purpose is to seek out, investigate, and potentially acquire an interest in a business opportunity. The company was incorporated in 1990 and is based in Ogden, Utah.
What do analysts say about BOTH stock?
As of March 18, 2026, there is no available analyst coverage for Bioethics, Ltd. due to its status as a shell company with no significant operations.
What are the main risks for BOTH?
The main risks associated with investing in Bioethics, Ltd. stem from its nature as a shell company. These include the risk of failing to identify a suitable acquisition target, which would render the company valueless. There is also the risk of dilution of shareholder value through future equity offerings to fund acquisitions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's status as a shell company.
- Financial data is based on available information and may not be comprehensive.